Status quo of hypercoagulation as a prognostic indicator following neoadjuvant immunochemotherapy in locally advanced gastric cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Tables (1-2)

Sum=0

Sep 15, 2025 (publication date) through Sep 15, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Sep 15, 2025; 17(9): 106868
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106868

Table 1 Comparison of overall survival and disease-free survival in patients with and without hypercoagulation

Group	OS	DFS
Patients with hypercoagulation	78%	68%
Patients with hypercoagulation	94.4%	87%
P value	0.023	0.039

OS: Overall survival; DFS: Disease-free survival.

Table 2 Hazard ratios for overall survival and disease-free survival in hypercoagulation

OS: Overall survival; DFS: Disease-free survival; HR: Hazard ratio.

Citation: Christodoulidis G, Bartzi D, Tsagkidou K, Koumarelas KE, Zacharoulis D. Status quo of hypercoagulation as a prognostic indicator following neoadjuvant immunochemotherapy in locally advanced gastric cancer. World J Gastrointest Oncol 2025; 17(9): 106868
URL: https://www.wjgnet.com/1948-5204/full/v17/i9/106868.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i9.106868